Brief: Virogates Starts Study To Validate suPARnostic For Guiding Early Anakinra Treatment Of COVID-19 Patients

ViroGates A/S

26/01/2021 13:35

Jan 26 (Reuters) - ViroGates A/S  VIROG.CO :
    * INITIATED CLINICAL STUDY TO CLINICALLY VALIDATE
SUPARNOSTIC FOR
GUIDING EARLY ANAKINRA TREATMENT OF COVID-19 PATIENTS
    * EXPLORATORY STUDY FROM OCTOBER 2020, CURRENTLY UNDERGOING
PEER
REVIEW, SHOWS INITIAL POSITIVE RESULTS USING SUPAR-GUIDED
ANAKINRA TREATMENT TO PREVENT SEVERE RESPIRATORY FAILURE (SRF)
FOR COVID-19 PATIENTS
    * STUDY TO BE CONDUCTED IN COLLABORATION WITH HISS (HELLENIC
INSTITUTE FOR STUDY OF SEPSIS)
    * RESULTS SHOWED THAT INCIDENCE OF SRF AMONG TREATED
PATIENTS WAS
22.3% COMPARED TO 59.2% AMONG UNTREATED COMPARATORS
    * MORTALITY AFTER 30 DAYS WAS 11.5% AND 22.3%, RESPECTIVELY.

Source text for Eikon:  ID:nNDL9fb1yd 
Further company coverage:  VIROG.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))